Regulatory Changes and Compliance Risk: The pharmaceutical industry in China is highly regulated, subject to frequent policy changes regarding drug approval, pricing, manufacturing standards, and market access, which could impact CPHI's operations and profitability.

Product Development and Approval Risk: There are inherent risks in pharmaceutical research and development, including clinical trial failures, delays in product registration, or inability to successfully bring new drugs to market, affecting future revenue streams.

Intellectual Property Protection Risk: Enforcing and protecting patents, trademarks, and other intellectual property rights in China can be challenging, leading to potential infringement by competitors and erosion of market share or innovation advantages.